Isomorphic Labs secures $2B+ Series C funding from Thrive Capital for AI drug discovery

Short summary

Isomorphic Labs, Alphabet's AI drug discovery subsidiary, is securing $2B+ in Series C funding led by Thrive Capital. The capital will expand its drug design engine and global reach. This reflects how major tech firms are aggressively funding applied AI in regulated domains like pharmaceuticals.

• •Isomorphic Labs (Alphabet's AI drug discovery unit) raises $2B+ Series C from Thrive Capital
• •Funding supports drug design engine expansion and international growth
• •Title mentions Anthropic but article covers Isomorphic Labs instead

Generated with AI, which can make mistakes.